CURRICULUM VITAE

Johannes G Ramaekers

Professional positions                    

1989-1997                              Project manager / Research scientist, Institute for Human Psychopharmacology,

Maastricht University, The Netherlands

1998-present                           Assistant Professor, Faculty of Psychology, Department of Neurocognition

Maastricht University, The Netherlands

Professional affiliations

British Association for Psychopharmacology (BAP), International Council of Alcohol, Drugs and Traffic Safety (ICADTS)

Collegium Internationale Neuro-Psychopharmacologicum (CINP), Federation of European Neuroscience Societies (FENS)

Research experience

Psychopharmacology, clinical & experimental , Schizophrenia, depression, anxiety, allergy, stroke and epilepsy.

Medicinal and illicit drugs, Pharmacodynamics and pharmacokinetics in Phase II, III and IV trials, Psychophysiology of information processing and vigilance, Traffic Psychology

Teaching experience

 Courses

 Coordinator of several courses and lecturer in the fields of Biological Psychology, Psychopharmacology, Neuropsychology and Cognitive Ergonomics as part of the curriculum of the Faculty of Psychology,and PhD courses at Maastricht University.

• Course coordinator: Environmental Psychology, 1998-1999
• Course coordinator: Traffic & Aviation Psychology 1999-2002
• Course coordinator: Human Psychopharmacology, PhD course, 1999-2002
• Course co-coordinator: Brain Damage, 1998-1999
• Course co-coordinator: Body and Behavior, 1998-2000
• Course co-coordinator: Man-Machine Interaction, 1999-2002
• Course co-coordinator: Activation, Arousal and Psychopharmacology 2002

PhD programs

 Principle investigator and co-promotor of PhD research programs at the Faculty of Psychology, Brain & Behavior Institute, Maastricht University

§         CTJ Lamers. Influence of marijuana and MDMA (ecstacy) on psychomotor functions, cognition and actual driving performance (1998-2002).

§         E Theunissen,  Histamine, sleep and performance (2001-2005)

§         K Kuypers.  3,4-methylenedioxymethamphetamine (MDMA) and alcohol interactions in humans: psychomotor performance, subjective effects and pharmacokinetics (2003-2007)

§         M Wingen: serotonergic and noradrenergic correlates of cognition and psychomotor function (2003-2007).

Co-investigator in a research program at the Faculty of Medicine (UM) on the vulnerability of schizophrenic patients, first-degree relatives and recreational cannabis users to the detrimental effects of cannabis on cognition and psychiatric status. (PhD student: Cecile Henquet; Promotor : Prof dr J van Os)

Management

• Chairman of the Experimental Psychopharmacology Unit (EPU). This interdisciplinary working group is part of the Brain & Behavior Institute and comprises staff Psychologists and staff physicians from the Faculty of Psychology as well as the Faculty of Medicine. The working group has currently 15 members, including 4 PhD students and one post-doc, and is dedicated to conducting research in the field of human psychopharmacology.
• Member of the Commissie OnderzoeksVoorzieningen (COV) at the Faculty of Psychology, Maastricht University

Conference organisation

• Organizer of an exhibition at the XXIInd congress of the Collegium Internationale NeuroPsychopharmacologicum (CINP) for promoting experimental Drugs & Driving research (Brussels, 2000)

• Organizer of an exhibition at the XIIIth congress of the European College of Neuro- Psychopharmacologicum (ECNP) for promoting experimental Drugs & Driving research (Munich, 2000)

• Member of the organisation committee and chairman at the annual conference of the Europe Chapter of the Human Factors and Ergonomics Society (Maastricht, 2000)

• Moderator and chairman of a symposium on the “behavioural toxicity of MDMA in humans” at the 5^th EndoNeuroMeeting of the Dutch Neurofederation (Doorwerth, 2001)

• Organizer of an exhibition at the XIVth congress of the European College of Neuro- Psychopharmacologicum (ECNP) for promoting experimental Drugs & Driving research (Istanbul, 2001)

• Moderator and chairman of a symposium on “neuro-behavioral effects of MDMA” at the XXIIIrd congress of the Collegium Internationale NeuroPsychopharmacologicum (CINP) (Montreal, 2002)

 Journal editorial work

• Executive guest editor of Current Pharmaceutical Design (2003-2008)
• Manuscript review: Allergy, Drug Safety, Psychopharmacology, Alcohol & Alcoholism, American Journal of Rhinology, British Medical Journal, Addiction, International Journal of Neuropsychopharmacology, Neurology.

Professional honours

• Recipient. Receipt of the Widmark Award (International Council of Alcohol, Drugs and Traffic Safety) “for numerous contributions to the advancement of the cause of alcohol, drugs and traffic safety and sustained contributions to the support in this field@. 1995 [In the name of the Institute for Human Psychopharmacology]

• Representative of the Netherlands. Seminar organised by the Council of Europe (Pompidou group) to combat drug abuse and driving under the influence. Representative of the Netherlands in a working group on prevalence, epidemiology and risk assessment (Strasbourg, 1999)

• Invited participant. International consultative 5-day meeting on drugs and driving impairment involving a 25-member expert panel of psychopharmacologists, toxicologists and US government representatives (Seattle, 2000)

• Invited speaker, for a series of lectures on the behavioural toxicity of antidepressants to physicians and pharmacists at psychiatric institutions, as part of a drug educational program organized by Organon NV (2000-2001)

• Participant, of an invitational conference on medicines and illicit drugs in traffic, organised by an interdepartmental project group of representatives of the Dutch Ministries of Justice, Home Affairs, Health, Welfare and Sports and the Ministry of Transport, Public Works and Water Management (The Hague, 2001).

• Invited speaker and participant, at the Cannabis Conference 2002. A joint international effort at the initiative of the ministers of public health of Belgium, France, Germany, The Netherlands and Switzerland. Published by the Ministry of Public Health of Belgium (Brussels, 2002).

• Invited speaker, for a lecture on the effects of marijuana on psychomotor performance and cognition at the annual meeting of the Society of Forensic Toxicologists (SOFT, Detroit, 2002).

• Invited speaker, at a Drugs & Driving workshop (‘The A-Z of marijuana’) of the Canadian Society of Forensic Science (CSFS) for a lecture on the effects of marijuana on psychomotor performance and cognition  (Vancouver, 2003).

Research projects

As Investigator: Institute for Human Psychopharmacology

• A subchronic comparison of high dose effects of terfenadine and loratadine on psychomotor test performance, actual driving and EEG during driving versus those of triprolidine and placebo. Supported by Merrel-Dow, 1989.
• A study to compare the effects of loratadine and cetirizine with and without ethanol on actual driving performance and EEG during driving. Supported by schering-Plough, 1990.
• A comparison of the subchronic effects of two doses of a new MAO-A inhibitor (brofaromine) on psychomotor performance and actual driving versus those of doxepin and placebo. Supported by Ciba-Geigy, 1990.
• A comparison of the subchronic effects of a new MAO-A inhibitor (moclobemide) on psychomotor performance and actual driving versus those of mianserin and placebo. Supported by F. Hoffman-La Roche, 1990.
• Comparison of the acute dose-effect relationship that determines the influence of acrivastine and terfenadine on actual driving performance. Supported by Burroughs-Wellcome, 1991.
• Comparative study of the acute and subchronic effects of dothiepin and fluoxetine versus placebo. Supported by Boots Compagny, 1992.
• A large scale combined clinical and psychometric study to compare the efficacies and  side effects of moclobemide and fluoxetine in outpatients suffering from major depression. Supported by F. Hoffman-La Roche, 1993
• A study to determine the subchronic effects of befloxatone (selective, reversible MAO-A inhibitor) with and without ethanol challenge on psychometric test performance. Supported by Synthelabo L.E.R.S., 1993.
• Comparative study to determine the acute and subchronic effects of mirtazapine and mianserin, in ascending doses, on actual driving and psychometric performance. Supported by Organon NV, 1994
• Subchronic comparison of the neuroleptics amisulpride and haloperidol, versus placebo, on cognitive and psychomotor functions, extrapyramidal side effects and psychiatric status of healthy volunteers. Supported by Synthelabo L.E.R.S., 1995
• Determination of the residual effects on actual driving of chlorpheniramine in doses of 8 and 12mg hs. Supported by Schering-Plough, 1996

As Principle Investigator: Faculty of Psychology, Brain & Behavior Institute.

§         Research program on the effects of marijuana smoking with and without ethanol on actual driving performance. Supported by the US National Highway Traffic Safety Administration (NHTSA), 1998-2000

§         Comparative study of the effects of the antiepileptics remacemide and carbamazapine, versus placebo, on actual driving performance. Supported by Astra-Zeneca, 1998.

§         A study of the acute effects of the antihistamine desloratadine on actual driving and psychometric test performance, versus those of diphenhydramine and placebo. Supported by Schering-Plough, 1999.

§         Comparison of the acute dose-effect relationship that determines the influence of mequitazine on actual driving and psychometric test performance, as compared to dexchlorpheniramine, cetirizine and placebo. Supported by Pierre-Fabre, 2000.

§         A comparison of the effects of mequitazine, cetirizine, dexchlorpheniramine and placebo on psychomotor test performance and actual driving during 8 days of repeated dosing. Supported by Pierre-Fabre, 2000.

§         Research program on the effects of MDMA (3,4-methylenedioxymethamphetamine) or “Ecstasy” on cognition, psychomotor function and actual driving performance in recreational users. Supported by the European Committee, 2002-2005.

§         Research program on the relative contributions of antidepressants’side effects and symptoms of depression to performance impairment in depressed outpatients. Supported by the European Committee, 2002-2005.

§         Literature review of experimental and epidemiological studies on performance impairment and motor vehicle crashes after cannabis use. Supported by the Dutch ministry of Health (VWS), 2002

§         A comparison of the effects of escitalopram , mirtazapine and placebo on psychomotor test performance and actual driving during 2 weeks of repeated dosing. Supported by Lundbeck, 2002.

Publications

 Journal articles

1. Ramaekers JG, Uiterwijk MMC, O=Hanlon JF (1992) Loratadine=s and cetirizine=s effects on actual driving and psychometric test performance, and EEG during driving. European Journal of Clinical Pharmacology 42(4): 363‑369
2. Ramaekers JG, Swijgman HF, O'Hanlon JF (1992) Effects of moclobemide and mianserin on highway driving, psychometric performance and subjective parameters, relative to placebo. Psychopharmacology 106 Suppl: S62‑67
3. Ramaekers JG, van Veggel LMA, O'Hanlon JF (1994) A cross‑study comparison of the effects of moclobemide and brofaromine on actual driving performance and estimated sleep. Clinical Neuropharmacology 17 Suppl 1: S9‑18
4. Ramaekers JG, O'Hanlon JF (1994) Acrivastine, terfenadine and diphenhydramine effects on driving performance as a function of dose and time after dosing. European Journal of Clinical Pharmacology 47(3): 261‑266
5. Ramaekers JG, Muntjewerff ND, O'Hanlon JF (1995) A comparative study of acute and subchronic effects of dothiepin, fluoxetine and placebo on psychomotor and actual driving performance. British Journal of Clinical Pharmacology 39(4): 397‑404
6. O'Hanlon JF, Ramaekers JG (1995) Antihistamine effects on actual driving performance in a standard test: a summary of Dutch experience, 1989‑94. Allergy 50(3): 234‑42
7. Ramaekers JG, Muntjewerff ND, Uiterwijk MMC, van Veggel LMA, Patat A, Durrieu G, O=Hanlon JF (1996) A study of the pharmacodynamic interaction between befloxatone and ethanol on performance and mood in healthy volunteers. Journal of Psychopharmacology 10(4): 288‑294
8. Ramaekers JG, Ansseau M, Muntjewerff ND, Sweens JP, O'Hanlon JF (1997) Considering the P450 cytochrome system as determining combined effects of antidepressants and benzodiazepines on actual driving performance of depressed outpatients. International Clinical Psychopharmacology 12(3): 159‑69
9. Ramaekers JG (1998) Behavioural toxicity of medicinal drugs. Practical consequences, incidence, management and avoidance. Drug Safety 18(3): 189‑208
10. Riedel WJ, Vermeeren A, van Boxtel MPJ, Vuurman EFPM, Verhey FRJ, Jolles J & Ramaekers JG (1998) Mechanisms of drug-induced driving impairment: a dimensional approach. Human Psychopharmacology 13 Suppl 2: S49-63
11. Vermeeren A, Ramaekers JG, van Leeuwen CJ, O=Hanlon JF (1998) Residual effects on actual car driving of evening doses of chlorpheniramine 8 and 12 mg when used with terfenadine 60mg in the morning. Human Psychopharmacology 13 Suppl 2: S79-86
12. Ramaekers JG, Muntjewerff ND, van Veggel LMA, Uiterwijk MMC, O=Hanlon JF (1998) Effects of nocturnal doses of mirtazapine and mianserin on sleep and on daytime psychomotor and driving performance in young, healthy volunteers. Human Psychopharmacology 13 Suppl 2: S87-97
13. Ramaekers JG (1998). Emerging drugs: the prospect for improved medicines (vol 3). Book review; Trends in Pharmacological Sciences 19: 518
14. Ramaekers JG, Louwerens JW, Muntjewerff ND, Milius H, de Bie A, Rosenzweig P, Patat A, O=Hanlon JF (1999) Psychomotor, cognitive, extrapyramidal and affective functions of healthy volunteers during subchronic treatment with an atypical (amisulpride) and a classic (haloperidol) antipsychotic. Journal of Clinical Psychopharmacology 19 : 209-221
15. Vermeeren A, Ramaekers JG, Vuurman EFPM, Riedel WJ (2000) Psychofarmaca en autorijden. Psychopraxis 2 : 216-224
16. Ramaekers JG, Robbe HWJ, O=Hanlon JF (2000) Marijuana, alcohol and actual driving performance. Human Psychopharmacology, Clinical & experimental 15 : 551-558
17. Ramaekers JG, Vermeeren A (2000) All antihistamines cross blood-brain barrier [comment]. British Medical Journal, 321 : 573
18. Lamers CTJ, Ramaekers JG (2001) Visual search and urban driving under the influence of marijuana and alcohol. Human Psychopharmacology Clin Exp 16: 393-40
19. Blokland A, Scholtissen B, Vermeeren A, Ramaekers JG (2001) Dissociable effects of H₁ antagonists on reaction  time performance in rats. Pharmacology, Biochemistry and Behavior,70 : 427-436
20. Vermeeren A, Ramaekers JG, O=Hanlon JF (2002) Effects of emedastine and cetirizine, alone and with alcohol, on actual driving performance of males and females. Journal of Psychopharmacology, 16: 45-52
21. Ramaekers JG, Lamers CTJ, Muntjewerff ND, Verhey F, Sanders N, Mobbs E, Lewis J, Lockton JA (2002) A comparative study of the effects of carbamazepine and the NMDA antagonist remacemide on Road Tracking and Car Following performance in actual traffic. Psychopharmacology, 159:203-210
22. Schmitt JAJ, Riedel WJ, Vuurman EFPM, Kruizinga M, Ramaekers JG (2002). Modulation of the critical flicker fusion effects of serotonin reuptake inhibitors by concomitant pupillary changes. Psychopharmacology, 160: 381-386.
23. Schmitt JAJ, Ramaekers JG, Kruizinga M, Teunisse S, Van Boxtel MPJ, Vuurman EFPM, Riedel WJ (2002) Additional dopamine reuptake inhibition prevents vigilance decrement induced by serotonergic reuptake inhibition in man. Journal of Psychopharmacology, 16 :207-214
24. Ramaekers JG (2003) Antidepressants and driver impairment: empirical evidence from a standard on-the-road test. Journal of Clinical Psychiatry, 64: 20-29
25. Ramaekers JG (2003) Pitfalls in estimating drug related crash risk. Trends in Pharmacological Sciences, 24: 114-115
26. Lamers CTJ, Ramaekers JG, Muntjewerff N, Samijn N, Sikkema K, Read L, Riedel W (2003) Dissociable effects of a single dose of MDMA on psychomotor skills and attentional performance. J of Psychopharmacology, accepted for publication
27. Ramaekers JG, Berghaus G, Van Laar M, Drummer OH (2003). Dose related risk of motor vehicle crashes after cannabis use. Drug and Alcohol Dependence, accepted for publication.
28. Vuurman EFPM, Rikken GH, Muntjewerff ND, de Halleux F, Ramaekers JG (2003) Effects of desloratadine, diphenhydramine and placebo on driving performance and psychometric measures.  Submitted for publication
29. Lamers CTJ, Ramaekers JG, Samijn N, Schmitt JAJ, Riedel W (2003) MDMA levels in four different human body fluids after a placebo-controlled single dose of MDMA predict changes in psychomotor performance, physiological activation and mood. Submitted for publication
30. Theunissen E, Vermeeren A, Oers van A, Maris van I, Ramaekers JG (2003) A dose-ranging study of mequitazine effects on actual driving, memory and attention as compared to dexchlorpheniramine, cetirizine and placebo. Submitted for publication
31. Lamers CTJ, Bechara A, Rizzo M, Ramaekers JG (2003) Cognitive function and mood in MDMA/THC users, THC users and non drug users. Submitted for publication
32. Lamers CTJ, Rizzo M, Bechara A, Ramaekers JG (2003) Comparison of simulated driving performance and attention of repeated users of MDMA and THC as compared to THC users and drug free controls. Submitted for publication

Books  

1. Ramaekers JG (1998) Behavioral Toxicity of Medicinal Drugs. Neuropsych Publishers, Maastricht University, Maastricht. ISBN 90-75579-07-1[Dissertation]
2. De Waard D, Weikert C, Hoonhout J, Ramaekers JG (2000) Human-System Interaction: Education, Research and Application in the  21^st Century. Proceedings of the HFES Europe Chapter Annual Meeting  in Maastricht, November 2000. Shaker Publishing BV, Maastricht. ISBN 90-423-0126-0

Book sections 

1. Ramaekers JG (2000). Marijuana and driving: risk assessment by experimental research. In : Pompidou Group (eds) Road Traffic and Drugs,  Council of Europe Publishing, Strasbourg, pp 231- 234
2. Ramaekers JG, Lamers CTJ, Robbe HWJ, O=Hanlon JF (2000) Low doses of alcohol and marijuana severely impair driving when taken together. In : Laurell H, Schlyter F (eds) Alcohol, Drugs and Traffic Safety-T2000, vol 3, Stockholm, pp 380-385
3. Ramaekers JG, Berghaus G, van Laar M, Drummer O (2002) Cannabis, performance impairment and  motor vehicle accidents. In : Spruit I (ed)  Cannabis 2002 report. A joint international effort at the initiative of the ministers of public health of Belgium, France, Germany, The Netherlands and Switzerland. Published by the Ministry of Public Health of Belgium, pp 79-96
4. Ramaekers JG (2003). Performance and behavioural effects of medicinal drugs. In :  M Burns (ed) Medical legal aspects of drugs. Lawyers & Judges Publishing Company, Tucson, Arizona, pp169-214
5. Schmitt JAJ, Lamers CTJ, Ramaekers JG, Riedel WJ (2003) Performance and behavioral effects of illicit drugs . In :  M Burns (ed) Medical legal aspects of drugs. Lawyers & Judges Publishing Company, Tucson, Arizona, 133-168

Technical reports

1. Ramaekers JG, Smid HGOM, Mulder LJM, Mulder G (1988). Multifeature processing and contineous flow. Department of Experimental and Occupational Psychology, State University of Groningen
2. Riedel WJ, Ramaekers JG, O=Hanlon JF (1990) Higher doses of terfenadine and loratadine, acute and subchronic effects on psychomotor and actual driving performance. IGVG 90-08
3. Ramaekers JG, van Boxtel M, O=Hanlon JF (1993) Acrivastine, Terfenadine and diphenhydramine effects on several aspects of actual driving performance as a function of time and time after dosing. IGVG 92-25
4. Ramaekers JG, O=Hanlon JF (1994) A comparative study of acute and subchronic effects of dothiepin and fluoxetine on psychomotor and actual driving performance. IHP 94-34
5. Ramaekers JG, Muntjewerff ND, Uiterwijk MMC, Van Veggel LMA, O=Hanlon JF (1995) A study of the possible pharmacodynamic interaction between befloxatone (20mg/day for 10 days) and ethanol on psychomotor performance in healthy volunteers (double blind, placebo controlled, cross-over study). IHP 95-42
6. Ramaekers JG, Muntjewerff ND, Uiterwijk MMC, Van Veggel LMA, O=Hanlon JF (1995) The effects of ascending doses of Org 3770 and mianserin on psychomotor performance and driving as compared to placebo. IHP 95-49
7. Vermeeren A, Van Leeuwen C, Muntjewerff ND, Faber R, Robbe H, Ramaekers JG, O=Hanlon JF (1995) A 4-way, double-blind, placebo and active drug controlled study for determining whether betahistine in single 32 and 54 mg doses enhances vigilance and cortical arousal in man. IHP 95-55
8. Ramaekers JG, Ansseau M, Muntjewerff ND, Sweens JP, O’Hanlon JF (1996) Moclobemide and fluoxetine effects on actual driving performance of outpatients suffering from major depression. IHP 96-31
9. Ramaekers JG, Louwerens JW, Muntjewerff ND, Milius H, De Bie A et al (1997) Effects of single and repeated doses of amisulpride (50 and 400mg/d) and haloperidol (4mg/d) on psychomotor, cognitive, extrapyramidal and affective functions in healthy, young volunteers. IHP 97-51
10. De Krom M, Folkertsma H, Ramaekers JG, Kessels  F, Lodder J (1997) Automobile driving performance after stroke in relation to CVA rankin score. Department of Neurology, Maastricht University.
11. Ramaekers JG, Van Leeuwen CJ, O=Hanlon JF (1997) A comparison of the residual effects of chlorpheneramine 8 and 12 mg, hs, when used with terfenadine 60 mg, qam, on the volunteers= driving performance versus those of placebo, and flurazepam 30mg, hs. IHP 97-58
12. Lamers CTJ, Ramaekers JG (2000) Visual search and urban city driving under the influence of marijuana and alcohol. Technical report DOT HS 809 020, U.S. Department of Transportation, NHTSA, Washington
13. Ramaekers JG, Lamers CTJ, Muntjewerff ND, Verhey F, Sanders N, Mobbs E, Lewis J, Lockton JA (2000) A comparative study of the effects of carbamazepine and the NMDA antagonist remacemide on Road Tracking and Car Following performance in actual traffic. EPU 2000-03
14. Vuurman EFPM, Ramaekers JG (2000) Comparative effects of SCH 34117, diphenhydramine and placebo on actual driving performance and psychometric functions. EPU 2000-05

Selected abstracts : paper and poster presentations

1. Ramaekers JG (1990) Effects of antihistamines on psychomotor performance, as assessed by car driving. Paper presented at a symposium on APsychomotor assessment of modern antihistamines: why it matters@. Effingham park, Gatwick.
2. Ramaekers JG, Swijgman H, O=Hanlon JF (1991) Moclobemide=s effect on selected psychometric parameters and actual car driving performance, relative to those of mianserin and placebo. Paper presented at the 1991 meeting of the Society of Biological Psychiatry, Florence. Biological Psychiatry 29: 265S
3. Ramaekers JG (1991) Cetirizine=s and loratadine =s effects on actual driving performance and EEG during driving. Paper presented at the European Congress of Allergology and Clinical Immunology (EAACI), Paris 1991.
4. Veggel van LMA, Ramaekers JG, Swijgman HF (1992) Brofaromine and moclobemide effects on psychomotor and actual driving performance. Paper presented at the 1992 meeting of the Collegium Internationale Neuro-Psychopharmacology (CINP), Nice. Clinical Neuropharmacology 15: S1, 148B
5. Ramaekers JG (1992) Acrivastine=s and Terfenadine=s effects on several aspects of actual driving performance as a function of dose and time after dosing. Poster presented at the European Congress of Allergology and Clinical Immunology (EAACI), Paris 1992.
6. Ramaekers JG, Muntjewerff ND, O=Hanlon JF (1993). Acute and subchronic effects of dothiepin, fluoxetine and placebo on psychometric performance and actual driving. Paper presented at the 1993 meeting of the European College of Neuro-Psychopharmacology (ECNP), Budapest. European Neuropsychopharmacology 3: 446
7. Ramaekers JG, Muntjewerff ND, Patat A, Durrieu G, O=Hanlon JF (1995) The interaction between befloxatone and ethanol on psychomotor performance. Poster presented at the 1995 meeting of the Britisch Association of psychopharmacology (BAP). Journal of Psychopharmacology 9:a38
8. Ramaekers JG, Muntjewerff ND, O=Hanlon JF (1995) Acute and subchronic effects of mirtazepine (15/30mg nocte) and mianserin (30/60mg nocte) on psychomotor and actual driving performance and sleep in healthy, young volunteers. Paper presented at the 1995 meeting of the European College of  Neuro-Psychopharmacology (ECNP), Venice. European Neuropsychopharmacology 5:294
9. Ramaekers JG, Ansseau M, Muntjewerff ND, Sweens P, O=Hanlon JF (1996) Role of benzodiazepine comedication in determining depressed patients driving performance during antidepressant (moclobemide and fluoxetine) therapy: results of a post-hoc analysis. Paper presented at the 1996 meeting of the Association of European Psychiatry (AEP), London. European Psychiatry 11: s240
10. Ramaekers JG (1997) Quantification of drug and alcohol effects on driving performance. Paper presented at the 1997 meeting of the European Society of Biomedical research on Alcoholism (ESBRA), Stockholm. Alcohol & Alcoholism 32: 314
11. Ramaekers JG, Louwerens JW, Muntjewerff ND, Milius H, De Bie A, Rosenzweig P, O’Hanlon JF (1997) Repeated dose effects of amisulpride 50 and 400 mg/day, haloperidol (4mg/day) and placebo upon hedonic, cognitive, psychomotor and extrapyramidal motor functions in healthy volunteers. Abstract presented at a workshop of the British Association for Psychopharmacology (BAP), Royal Society, London 15 March 1996.  Included as appendix to a BAP consensus statement on guidelines for the use of antipsychotic drug studies in healthy volunteers. Journal of Psychopharmacology 11: 201-209.
12. De Bruin A, Vuurman E, Lamers C, Ramaekers JG, Vermeeren A, Riedel WJ (1998). Drugs and driving : a review. Poster presented at the 1998 meeting of the British Association of Psychopharmacology (BAP). Journal of Psychopharmacology 12:a46
13. De Krom MCTFM, Steinbusch AJWH, Custers A, Folkertsma H, Ramaekers JG, Kessels AGH, Heuts-Van Raak EPM, Lodder J (1998) Resuming car driving within 1 year in stroke survivors in the Netherlands: some have the fitness, none is allowed. Clinical Neurology and Neurosurgery 100: 304
14. O’Hanlon JF, Ramaekers JG, Louwerens JW, Rosenzweig P (1998). Amisulpride and haloperidol effects on affective, cognitive and psychomotor fucntions in healthy volunteers. Poster presented at the 1998 meeting of the Collegium Internationale Neuro-Psychopharmacology (CINP), Glasgow (abstract PT 10066).
15. Ramaekers JG (1999) Marijuana and driving: risk assessment by experimental research. Paper presented   at a seminar on ‘Road traffic and illicit drugs’ organised by the Pompidou Group, Council of Europe, Strasbourg.
16. Lamers CTJ, Ramaekers JG (1999) Marijuana and alcohol effects on visual search and general driving proficiency. Poster presented at the 1999 meeting of the British Association of Psychopharmacology (BAP). Journal of Psychopharmacology 13:a53
17. Vuurman EFPM, Ramaekers JG, Rikken G, De Halleux F (2000). Desloratadine does not impair actual driving performance: a 3-way crossover comparison with diphenhydramine and placebo.  Paper presented  at the European Congress of Allergology and Clinical Immunology (EAACI), Lisbon 2000 [abstract 996].
18. Vermeeren A, Ramaekers JG, O’Hanlon JF (2001) Effects on actual car driving performance of the selective H1-antagonists, emedastine and cetirzine, alone and with alcohol.Paper presented at the 2001 meeting of the European College of  Neuro-Psychopharmacology (ECNP), Istanbul [abstract P6.028]
19. Schmitt JAJ, Riedel WJ, Vuurman EFPM, Ramaekers JG (2001) Acute critical flicker fusion effects of serotonin reuptake inhibitors are modulated by concomitant pupillary changes. Paper presented at the 2001 meeting of the European College of  Neuro-Psychopharmacology (ECNP), Istanbul [abstract P1.049]
20. Riedel WJ, Schmitt JAJ, Lamers CTJ, Ramaekers JG (2001) Assessment of route navigational memory in actual city traffic as a measure of attentional capacity under the influence of drugs: Rationale and application of a new test. Paper presented at the 2001 meeting of the European College of  Neuro-Psychopharmacology (ECNP), Istanbul [abstract P5.012]